Use of a synaptosomal model to monitor drug-induced in vivo changes in the gamma-aminobutyric acid content of nerve endings and its relevance to research on antipsychotic drugs.
The validity of a synaptosomal nuclei model to monitor drug-induced changes in the gamma-aminobutyric acid (GABA) content of nerve endings is reviewed. Examples of data obtained using the model are presented and the possibility of using the model for research on antipsychotic drugs is discussed.